MOTS-c
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by mitochondrial DNA. It has attracted attention because of its links to energy metabolism, insulin sensitivity, exercise biology and aging. The biology is compelling. But most therapeutic claims still rest on cell and animal research—not controlled human trials of administered MOTS-c.
Human therapy unproven.
Human studies support MOTS-c as an endogenous metabolic and exercise-responsive signal. They do not yet establish injected MOTS-c as a safe or effective treatment.
A signal from the mitochondria.
MOTS-c belongs to a relatively new class of mitochondrial-derived peptides—small signaling molecules encoded within mitochondrial DNA.
Research suggests MOTS-c participates in metabolic adaptation, glucose handling and cellular stress responses. One proposed pathway involves AMPK, a central cellular energy sensor. Under metabolic stress, MOTS-c has also been reported to translocate to the nucleus, linking mitochondrial state with nuclear gene expression.
Humans make MOTS-c. That is not the same as proving MOTS-c therapy.
Human research has shown that endogenous MOTS-c changes in response to physiology. A 2021 study found that acute endurance exercise increased circulating mitochondrial-derived peptides including MOTS-c, while acute resistance exercise did not produce the same response. Other human studies have examined circulating MOTS-c levels, genetic variants and metabolic associations.
Those studies matter because they support MOTS-c as a genuine human biological signal. But they answer a different question from whether externally administered MOTS-c improves fat loss, endurance, insulin sensitivity or longevity in humans.
Where mitochondrial excitement becomes therapeutic hype.
The biology is ahead of the therapy.
High optimization interest
Online conversations tend to cluster around energy, endurance, glucose control, fat metabolism, mitochondrial health and “exercise mimetic” effects.
- Performance and stamina claims
- Metabolic-health positioning
- Frequent stacking with other mitochondrial compounds
- Longevity framing despite limited therapeutic human data
Biology, not therapy
Human studies support the existence and physiologic responsiveness of endogenous MOTS-c, including exercise-related changes and associations with metabolic traits.
- Endogenous MOTS-c detectable in humans
- Exercise-responsive signaling documented
- Human genetic/association studies exist
- No established therapeutic efficacy for administered MOTS-c
The key distinction is simple: evidence that the human body uses MOTS-c is not evidence that injected MOTS-c produces the same benefits. Community enthusiasm often collapses those two ideas into one.
Unknown is doing a lot of work here.
MOTS-c does not have an FDA-approved drug product, and the safety profile of administered MOTS-c in humans is not well characterized.
FDA has identified potential significant safety concerns for compounded MOTS-c, including possible immunogenicity depending on route and concerns related to peptide impurities and characterization. In its July 2026 review, FDA stated that there was a lack of clinical and nonclinical safety information and a lack of human data on MOTS-c drug products administered by any route.
MOTS-c moved from obscure biology into regulatory focus.
Regulatory
FDA formally reviewed MOTS-c-related bulk drug substances.
The Pharmacy Compounding Advisory Committee considered MOTS-c free base and acetate for potential 503A Bulks List inclusion, with obesity and osteoporosis as the evaluated uses. FDA’s review proposed against inclusion because of limited characterization, lack of human administration data, insufficient effectiveness evidence and unresolved safety questions.
Research
Human exercise biology strengthened the endogenous signal story.
A human study reported that acute endurance exercise increased circulating mitochondrial-derived peptides including MOTS-c, reinforcing its role as an exercise-responsive biological signal without establishing therapeutic use.
Research
The foundational metabolic paper put MOTS-c on the map.
Preclinical research reported improved glucose metabolism and protection against diet-induced obesity and insulin resistance in mice, helping launch much of the metabolic interest that followed.
Show the receipts.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| Foundational MOTS-c paper · PMID 25738459 | Cell + mouse studies | Established MOTS-c as a mitochondrial-derived metabolic peptide; showed protection against diet-induced obesity and insulin resistance in mice. | Does not establish human therapeutic efficacy. |
| Exercise physiology · PMID 34351816 | Human acute exercise study | Supports endogenous MOTS-c as an exercise-responsive human signal. | Does not show that administered MOTS-c improves performance. |
| Genetic/metabolic study · PMID 33468709 | Human cohorts + mouse experiments | Links a MOTS-c mitochondrial DNA variant with diabetes risk and physical activity interactions. | Genetic association is not proof that MOTS-c administration treats diabetes. |
| FDA 2026 compounding review | Regulatory evidence review | Documents the lack of human administration data and unresolved safety / effectiveness questions for compounded MOTS-c. | Does not determine whether future pharmaceutical development could eventually prove benefit. |
Read deeper.
Follow the evidence.
Cellular Energy
Explore mitochondrial signaling, metabolic flexibility and the compounds being discussed around cellular energy.
Tesamorelin
Contrast MOTS-c’s preclinical-heavy story with a peptide backed by randomized human trials and an FDA-approved indication.
Retatrutide
See what a much deeper metabolic clinical-development program looks like.
SS-31 / Elamipretide
Compare endogenous mitochondrial biology with a mitochondria-targeting peptide that now has randomized human trials and an FDA-approved indication.